KTTA: חוב כולל להון Pasithea

This chart of market price action for the total debt-to-equity ratio of Pasithea Therapeutics (KTTA) stands at 0.00, correlating with progress in developing CNS pathology treatments and potential acquisition deals. The business relies on the development of innovative treatments for psychiatric disorders, capturing vacant market niches. Meanwhile, current research expenditures in the absence of sales are already priced in.

This ratio measures the extent of the business's dependence on external borrowings relative to its own equity, determining the risk of excessive financial leverage and the balance sheet's resilience to crises. Analyzing the proportion of total debt to equity for Pasithea Therapeutics (KTTA) is critically important, as the lack of stable revenues and high research costs make the company vulnerable to any debt obligations.